COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER

被引：0
|
作者：
Nguyen, T. T. T. [1 ]
Yagudina, R. [2 ]
Kulikov, A. U. [3 ]
机构：
[1] First Moscow State Med Univ Named Sechenov, Moscow, Russia
[2] Moscow Med Acad, Lab Pharmacoecon, Moscow, Russia
[3] Moscow Med Acad, Moscow, Russia
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
10.1016/j.jval.2011.02.916
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A165 / A165
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of adjuvant therapy with trastuzumab for early breast cancer
    Wardley, Andrew M.
    Cameron, David A.
    Bell, Richard
    Erny, Samuel
    Cohen, Carole
    Geary, Una
    Walzer, Stefan
    Gyldmark, Marlene
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 95 - 96
  • [32] Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer
    Fagnani, Francis
    Colin, Xavier
    Arveux, Patrick
    Coudert, Bruno
    Misset, Jean-Louis
    [J]. BULLETIN DU CANCER, 2007, 94 (7-8) : 711 - 720
  • [33] KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer
    Mamounas, Eleftherios P.
    Geyer, Charles E., Jr.
    Huang, Chiun-Sheng
    Mano, Max S.
    Loibl, Sibylle
    Untch, Michael
    Wolmark, Norman
    Rastogi, Priya
    Schneeweiss, Andreas
    Redondo, Andres
    Fischer, Hans H.
    Jacot, William
    Conlin, Alison K.
    Arce-Salinas, Claudia
    Wapnir, Irene L.
    Jackisch, Christian
    DiGiovanna, Michael P.
    Fasching, Peter A.
    Crown, John P.
    Wuelfing, Pia
    Shao, Zhimin
    Caremoli, Elena Rota
    Wu, Haiyan
    Lam, Lisa H.
    Tesarowski, David
    Smitt, Melanie
    Douthwaite, Hannah
    Singel, Stina M.
    von Minckwitz, Gunter
    [J]. SWISS MEDICAL WEEKLY, 2019, 149 : 13S - 13S
  • [34] Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada
    Attard, C. L.
    Pepper, A. N.
    Brown, S. T.
    Thompson, M. F.
    Thuresson, P. -O.
    Yunger, S.
    Dent, S.
    Paterson, A. H.
    Wells, G. A.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (03) : 173 - 188
  • [35] Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer
    Gershon, Noga
    Berchenko, Yakir
    Hall, Peter S.
    Goldstein, Daniel A.
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2019, 17 (1)
  • [36] Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States
    Garrison, Louis P., Jr.
    Babigumira, Joseph
    Tournier, Clement
    Goertz, Hans-Peter
    Lubinga, Solomon J.
    Perez, Edith A.
    [J]. VALUE IN HEALTH, 2019, 22 (04) : 408 - 415
  • [37] Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer
    Noga Gershon
    Yakir Berchenko
    Peter S. Hall
    Daniel A. Goldstein
    [J]. Cost Effectiveness and Resource Allocation, 17
  • [38] Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer
    Haq, Bushra
    Geyer, Charles E.
    [J]. WOMENS HEALTH, 2009, 5 (02) : 135 - 147
  • [39] A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer
    Kurian, Allison W.
    Newton Thompson, Rebecca
    Gaw, Allison F.
    Arai, Sally
    Ortiz, Rafael
    Garber, Alan M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (06) : 634 - 641
  • [40] Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China
    Zhang, Huahua
    Zhang, Yandong
    Huang, Chaonan
    Wang, Jiangfeng
    [J]. CLINICAL DRUG INVESTIGATION, 2021, 41 (06) : 569 - 577
12345